References
- Lindsay R, Hart DM, Aither JM, MacDonald EB, Anderson JB, Clarke AC. Long term prevention of menopausal osteoporosis by oestrogen. Lancet 1976;1:1038–41
- Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fractures in the use of estrogens in postmenopausal women. The Framingham study. N Engl J Med 1987;317: 1169–74
- Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantita-tive assessment of the epidemiological evidence. Prey Med 1991;20:47–63
- Grady D, Herrington D, Bittner V, et al. Cardio-vascular disease outcomes during 6.8 years of hormone therapy (HERS II). J Am Med Assoc 2002;288: 49–57
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321–33
- Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. N Engl J Med 1992;326:852–6
- Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumours. J Natl Cancer Inst, 2001;93:684–90
- Mountfield RJ, Kiehr B, John BA. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Drug Me tab Dispos 2000; 28:503–13
- Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby SO, Stender S. A partial estrogen receptor agonist with strong anti-atherogenic properties without noticeable effect on repro- ductive tissue in cholesterol-fed female and male rabbits. Arteriol Thromb Vasc Biol 1997;17: 2264–72
- Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001;86:755–60
- Black u, Sato M, Rowley ER, et al. Raloxifene prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovari-ectomized rats. J Clin Invest 1994;93:63–9
- Johnston CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med 2000;160:11–25
- Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
- Barrett-Connor E, Grady D, Sashegyi A, et al. The MORE Investigators. Raloxifene and cardio-vascular events in osteoporotic postmenopausal women; 4 year results from the MORE random-ised trial. J Am Med Assoc 2002;287: 847–57
- Bloch-Thomsen A, Silvestri S, Haarbo J, Christiansen C, Bjarnason NH. Association between target organ responses during hormone replacement therapy; bone versus lipids. Presented at the 10th World Congress on Menopause, Berlin, June 2002, F-05-05. Maturitas 2002; in press
- Campbell M, Machin D. Medical Statistics, a Commonsense Approach. Common Pitfalls in Medical Statistics. Chichester: Wiley, 1999: 138–49
- Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) actions. J Pharmacol Exp Ther 2000;295:431–7
- Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485–92
- Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. J Am Med Assoc 1999;282:637–45
- Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turn-over and serum lipids in early postmenopausal women: three year data from two double-blind, randomised, placebo controlled trials. Arch Intern Med 2000;160: 3444–51
- Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998;279:1445–51
- Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392–5